After Mylan (MYL) raised the price of its EpiPen by 400 percent, sparking a wave of controversy, the company now says it will offer a savings card worth $300 to users, effectively cutting the drug price in half. This comes after Democratic presidential candidate Hillary Clinton criticized the price increase on Twitter Wednesday. The EpiPen is a life saving drug for those suffering from severe allergies. Shares of Mylan, which initially slumped following news of the price hike, rose three percent on news of the price relief. TheStreet's Scott Gamm reports from Wall Street.
More from Video
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.